
|Videos|October 25, 2016
Results of a First-Line Study of Pembrolizumab in Advanced Urothelial Cancer
Author(s)Arjun Balar, MD
Arjun Balar, MD, assistant professor of medicine, Division of Hematology & Oncology, New York University Cancer Institute, NYU Langone Medical Center, discusses the results of a recent first-line study of pembrolizumab in advanced urothelial cancer.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Priority Review to Gedatolisib for Advanced Breast Cancer
2
FDA Grants BTD to Sofetabart Mipitecan for Platinum-Resistant Ovarian Cancer
3
RFS Benefit Sustained at 5 Years for Intismeran Autogene in Melanoma
4
3 Trials Refine Endocrine, HER2-Targeted Therapies at SABCS
5














































